On Sept. 14, 2020, Regeneron and the University of Oxford announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world’s largest randomized clinical trials of potential COVID-19 treatments, planned to evaluate Regeneron’s investigational anti-viral antibody cocktail, REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 compared the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.